Losartan Market Growth, Demand & Size by 2034
Coverage: By Indication (Blood Pressure, Stroke, Heart Disease); Route of Administration (Oral) , and Geography (North America, Europe, Asia Pacific, and South and Central America)
- Status : Data Released
- Report Code : TIPRE00017473
- Category : Life Sciences
- No. of Pages : 150
- Available Report Formats :

- Last update date : April 17, 2026
2025 Market Size
US$ 1.46 Bn
Base year value
2034 Forecast
US$ 2.31 Bn
Projected by 2034
CAGR 2026-2034
5.21 %
Growth rate
Addressable Market
US$ 17.08 Bn
(2026-2034)
The global losartan market size is projected to reach US$ 2.31 billion by 2034 from US$ 1.46 billion in 2025. The market is anticipated to register a CAGR of 5.21% during the forecast period 2026-2034.
The report is segmented by Indication (Blood Pressure, Stroke, Heart Disease); and Route of Administration (Oral). The global analysis is broken down at the regional level and for major countries. The market evaluation is presented in US$ for the above segmental analysis.
Market Assessment and Insights
- Global market for Losartan was valued at US$ 1.46 Billion in 2025
- Annual market size is expected to reach US$ 2.31 Billion by 2034
- Total addressable market (TAM) during 2026-2034 is projected to reach approximately US$ 17.08 Billion
- Market is anticipated to register a CAGR of 5.21% during the forecast period
- The United States represents a key market, supported by Increasing Prevalence of Hypertension, Rising Cardiovascular Disease Burden, Expanding Geriatric Population, as well as evolving industry dynamics
- Market analysis covers North America, Europe, Asia-Pacific, South and Central America, Middle East and Africa, with growth evaluated across the forecast period
- Market opportunities such as Expanding Role of Losartan in Post-Operative Care, Expanding Availability of Generic Losartan, Growing Adoption in Chronic Kidney Disease (CKD) Management are expected to influence market dynamics and addressable market
- Report profiles industry participants, including Torrent Pharmaceuticals, Macleods Pharmaceuticals, Merck, Teva Pharmaceuticals, Lupin, Cipla, Sandoz, Sun Pharmaceuticals, Unichem Laboratories, Dr. Reddy's Laboratories., while analyzing competitive strategies and innovation developments
-
Source: The Insight Partners' analysis based on proprietary research, government publications, company annual reports, investor presentations, industry databases, and expert interviews.
● REPORT CUSTOMIZATION
Tailor This Report To Align With Your Specific Business Requirements
This report can be customized to align precisely with your business objectives, scope, and target markets. Customization options include tailored segmentation, geography, competitive analysis, and strategic insights to support informed decision-making.
Customize This Report →WHAT YOU CAN ADJUST
- ● Segmentations
- ● Geography
- ● Competitive Analysis
- ● Language Preferences
Losartan Market: Strategic Insights
-
Get Top Key Market Trends of this report.This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Purpose of the Report
The report Losartan Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
-
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Losartan Market Segmentation Indication
-
- Blood Pressure
- Stroke
- Heart Disease
Route of Administration
-
- Oral
Losartan Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2025 | US$ 1.46 Billion |
| Market Size by 2034 | US$ 2.31 Billion |
| Global CAGR (2026 - 2034) | 5.21% |
| Historical Data | 2021-2024 |
| Forecast period | 2026-2034 |
| Segments Covered |
By Indication
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
Losartan Market Players Density: Understanding Its Impact on Business Dynamics
The Losartan Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Losartan Market Growth Drivers
-
- Increasing Prevalence of Hypertension: The Losartan market is driven by the expanding worldwide prevalence of hypertension. High blood pressure affects a substantial number of adults everywhere and leads to cardiovascular diseases as well as stroke and kidney damage. The aging global population means more people will develop hypertension which will increase the need for antihypertensive drugs such as Losartan. Healthcare professionals often prescribe Losartan because this angiotensin II receptor blocker (ARB) helps manage blood pressure through vessel relaxation which assists heart pumping.
The Losartan market is set to expand as hypertension becomes more prevalent because of lifestyle elements including poor diet, insufficient physical activity and high stress levels. As more people understand the dangers of untreated high blood pressure they seek medical treatment which boosts demand for blood pressure medications such as Losartan. Healthcare providers who work to improve patient outcomes and prevent high blood pressure complications anticipate an increase in Losartan usage as a primary treatment. Doctors and patients choose Losartan because its ability to lower blood pressure and diminish heart disease risk proves highly effective. The Losartan market is projected to grow in the coming years because hypertension is becoming more common worldwide while cardiovascular health management gains importance.
- Rising Cardiovascular Disease Burden: The Losartan market continues to grow primarily because of the increasing worldwide prevalence of cardiovascular diseases (CVDs). Heart failure, coronary artery disease, and stroke are included among CVDs which stand as the top mortality causes worldwide. The growing population of people suffering from hypertension combined with diabetes, obesity and smoking habits leads to more cases of cardiovascular diseases (CVDs). Losartan serves as a vital treatment for hypertension because it reduces heart strain which is essential for protecting patients who have a high chance of heart failure and stroke. Losartan helps lower blood pressure and enhance heart function by blocking angiotensin II which constricts blood vessels to increase blood pressure and this effect reduces cardiovascular complication risks.
Losartan serves as a treatment for hypertension and is prescribed to heart failure patients and those with chronic kidney disease because it protects renal function while decreasing chances of additional damage. The global increase in cardiovascular diseases especially among older adults drives up demand for effective treatment options such as Losartan. Increased awareness about early cardiovascular disease risk management advances Losartan market expansion. Healthcare providers will probably maintain their prescription practices for Losartan due to its dual advantages in blood pressure regulation and cardiovascular complication prevention which leads to continuous market growth.
- Expanding Geriatric Population: The Losartan market is expanding because the geriatric population continues to grow. The global increase in life expectancy leads to a higher number of older adults who need medical care for conditions like hypertension and cardiovascular diseases. As people age their cardiovascular systems naturally change including arterial stiffening which makes hypertension a common condition in elderly populations. The heart must work harder to pump blood when it encounters difficulty which results in higher blood pressure levels. Doctors commonly prescribe Losartan to older adults with hypertension because it helps lower their risk of heart failure along with stroke and kidney problems. Seniors usually have several concurrent health problems which necessitate complicated medical treatment plans. Older patients prefer Losartan for hypertension treatment because it demonstrates high effectiveness with minimal side effects. Losartan proves helpful for older patients who have diabetes and chronic kidney disease which frequently occur together in aged individuals. The growing elderly population in developed nations with aging populations will increase the need for Losartan. The increasing elderly population creates a major market expansion possibility for pharmaceutical companies that produce Losartan because they can now focus on this high-risk demographic to control hypertension and prevent cardiovascular diseases.
Losartan Market Future Trends
-
- Growing Preference for Combination Therapies: The Losartan market shows a growing trend towards combination therapies. Patients suffering from hypertension and cardiovascular diseases need multiple medications to reach ideal blood pressure control. The use of combination therapies that pair Losartan with antihypertensive agents like calcium channel blockers, diuretics or ACE inhibitors is on the rise. Combination products enhance treatment regimens by making them simpler and improving patient adherence while offering a broader approach to blood pressure management. Losartan frequently pairs with hydrochlorothiazide to increase its blood pressure-reducing capabilities. The trend emerges from increasing awareness about the advantages of combined drug treatments for complex medical conditions.
Individuals who have multiple health risks like diabetes along with high cholesterol and obesity commonly need multiple medications to control their blood pressure and decrease their chances of cardiovascular issues. Patients find combination therapies more convenient since they need to take fewer pills every day which helps them adhere better to their medication regimen. As combination therapies become more popular for treating hypertension and cardiovascular diseases Losartan market growth will persist because doctors and patients are searching for treatments that combine effectiveness with convenience.
- Rising Patient Preference for Single-Dose Combination Products: Patient preference for single-dose combination medications is growing which is reshaping the Losartan market. Hypertensive patients and those with cardiovascular conditions find it difficult to follow medication schedules since they need to take multiple pills daily. Multiple health conditions require management by older adults so they frequently encounter this problem. Pharmaceutical manufacturers developed combination tablets which pair Losartan with other blood pressure medications to address this issue. Medication regimens become simpler to manage with combination products which boosts patient adherence essential to effective hypertension treatment. The medication Losartan is commonly combined with diuretics or calcium channel blockers and other angiotensin receptor blockers (ARBs) to improve blood pressure management through a unified treatment approach. Better medical results occur when patients use single-dose combination pills because they follow their medication schedule properly.
The demand for Losartan combination products will rise as healthcare providers seek better hypertension management and patient adherence. Hypertension stands as the main source behind cardiovascular events and strokes and kidney damage which makes this pattern important. Single-dose combination therapies from pharmaceutical companies address both patient requirements in healthcare management and a major challenge encountered in chronic disease treatment. The Losartan combination therapies market will likely expand because individuals are learning more about the importance of following their medication schedules.
- Increasing Regulatory Support for Hypertension Treatments: The Losartan treatment market benefits from expanding regulatory support which favors hypertension therapies. Worldwide health authorities and governments now recognize the impact of hypertension on public health systems so they are focusing on improving its diagnosis and treatment. Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) established fast-track approval pathways for drugs proven effective and safe against hypertension and cardiovascular conditions. Due to the regulatory framework healthcare systems can develop and introduce new treatments such as Losartan and its combination medications to market. Healthcare institutions started programs aimed at reducing hypertension incidence and improving patient outcomes through better treatment methods. The enhanced attention healthcare systems give to hypertension management will increase Losartan's use because of its proven effectiveness and regulatory backing. The Losartan market will benefit from supportive regulatory measures and medical research developments targeting hypertension treatment in the upcoming years.
Losartan Market Opportunities
-
- Expanding Role of Losartan in Post-Operative Care: The availability of generic Losartan presents a significant opportunity for the global market. Following major surgical procedures such as cardiovascular or renal operations patients commonly face risks including hypertension along with fluid retention and kidney damage. The medication Losartan which can dilate blood vessels to lower blood pressure is now more frequently used in post-operative treatment to handle associated risks. The renal protective properties of this medication benefit patients who undergo kidney surgeries and patients with existing kidney conditions who face potential damage during their recovery period. The increasing frequency of cardiovascular operations such as coronary artery bypass grafting (CABG) and valve replacement surgeries requires more critical attention to manage patients' blood pressure after surgery. During recovery Losartan reduces heart and circulatory system strain which leads to lowered risks of complications such as stroke or heart failure.
Frequently Asked Questions
Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.
Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.
- Comprehensive Market Sizing and Forecast Analysis
- Detailed Segmentation Analysis
- In-Depth Market Dynamics Assessment
- Regional and Country-Level Insights
- Competitive Landscape and Company Benchmarking
- Strategic Business Intelligence
Recent Reports
Testimonials
The Insight Partners' SCADA System Market report is comprehensive, with valuable insights on current trends and future forecasts. The team was highly professional, responsive, and supportive throughout. We are very satisfied and highly recommend their services.
RAN KEDEM Partner, Reali Technologies LTDsI requested a report on a very specific software market and the team produced the report in a few days. The information was very relevant and well presented. I then requested some changes and additions to the report. The team was again very responsive and I got the final report in less than a week.
JEAN-HERVE JENN Chairman, Future AnalyticaWe worked with The Insight Partners for an important market study and forecast. They gave us clear insights into opportunities and risks, which helped shape our plans. Their research was easy to use and based on solid data. It helped us make smart, confident decisions. We highly recommend them.
PIYUSH NAGPAL Sr. Vice President, High Beam GlobalThe Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
YUKIHIKO ADACHI CEO, Deep Blue, LLC.This is the first time I have purchased a market report from The Insight Partners.While I was unsure at first, I visited their web site and felt more comfortable to take the risk and purchase a market report.I am completely satisfied with the quality of the report and customer service. I had several questions and comments with the initial report, but after a couple of dialogs over email with their analyst I believe I have a report that I can use as input to our strategic planning process.Thank you so much for taking the extra time and making this a positive experience.I will definitely recommend your service to others and you will be my first call when we need further market data.
JOHN SUZUKI President and Chief Executive Officer, Board Director, BK TechnologiesI wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA MANAGING DIRECTOR, PineCrest Healthcare Ltd.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Identifying Emerging Markets
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Boosting Operational Efficiency
- Strategic Planning
- Investment Justification
- Tracking Industry Innovations
- Aligning with Regulatory Trends